Amoxicillin-clavulanate Alone or in Combination With Ciprofloxacin in Low-Risk Febrile Neutropenic Adult Patients: A Prospective, Double-blind, Randomized, Non-Inferiority Multicenter, Phase III Clinical Trial. (ACACIA)

Poitiers University Hospital

Status and phase: Withdrawn; Phase 3

Conditions: Febrile Neutropenia

Treatments: Drug: Placebo; Drug: Ciprofloxacin; Drug: Amoxicillin Clavulanate

Study type: Interventional

Funder types: Other

Identifiers

NCT04698057

ACACIA

Details and patient eligibility

About

In low risk neutropenic fever in cancer, standard of care is the association of amoxicillin clavulanate and ciprofloxacin. But in this population, the rate of fever related to infection is very low, leading to a overtreatment of the patients. The aim of this study is to validate a descalation of the antibiotherapy with safety concerns.

Sex: All

Ages: 18 to 110 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient ≥ 18 years old
• Treated for a solid cancer or a hematological malignancy
• Presented with low-risk* febrile neutropenia due to chemotherapy with an expected duration of neutropenia ≤ 7 days
• Neutropenia is defined by an absolute neutrophil count ≤ 500/mm3.
• Fever is defined by temperature ≥ 38.3° or ≥ 38° twice during a 1-hour interval.
• Signing informed consent *Low risk is defined by MASCC score ≥ 21

Exclusion criteria

• Hypersensitivity to the active substances: amoxicillin-clavulanic, ciprofloxacin, penicillins, to other quinolones or to one of the excipient
• History of severe immediate hypersensitivity reaction to another beta-lactam
• History of jaunditis/hepatic impairment related to amoxicillin/clavulanic
• Concomitant administration of ciprofloxacin and tizanidine.
• Clinical signs of focal infection including history of untreated dental abscess.
• Signs of sepsis or organ failure.
• Severe immune deficiency other than the current cancer, except controlled-HIV infection
• Gastrointestinal symptoms requiring intravenous treatment (mucositis, vomiting, severe diarrhea...).
• Known aminotransferase serum levels > 5 x normal values.
• Known renal insufficiency defined as creatinine clearance of < 30 mL/min (MDRD).
• Antibiotherapy within 24h before enrollment. Prophylactic use of amoxicillin is an exclusion criterium whereas prophylactic use of trimethoprim-sulfamethoxazole (cotrimoxazole) and penicillin G (Oracilline®) are not and will be considered in the analysis.
• History of infection or colonization due to bacteria resistant to experimental drugs in the previous year
• Can be enrolled in the study only once.
• Patients not benefiting from a Social Security scheme or not benefiting from it through a third party.
• Persons benefiting from enhanced protection, namely minors, persons deprived of their liberty by a judicial or administrative decision, persons staying in a health or social institution, adults under legal protection, and finally patients in emergencies
• Pregnant or breastfeeding women, women at age to procreate and not using effective contraception (either hormonal / mechanical : oral, injection, subcutaneous, implantable, intrauterine device, or surgical : tubal ligation, hysterectomy, total ovariectomy).

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

0 participants in 2 patient groups

Amoxicillin clavulanate + ciprofloxacin

Active Comparator group

Description:

Treatment with amoxicillin-clavulanate 1g tib and ciprofloxacine 750mg bid for 5 days

Treatment:

Drug: Ciprofloxacin

Drug: Amoxicillin Clavulanate

Amoxicillin clavulanate + Placebo

Experimental group

Description:

Treatment with amoxicillin-clavulanate 1g tib for 5 days

Treatment:

Drug: Placebo

Drug: Amoxicillin Clavulanate